← Back
SAN GIOVANNI
December, 07th | 10:30 - 11:30
WET AMD TREATMENT 2
Add to calendar
Chairs: BROWN DAVID, GALE RICHARD, HEIER JEFFREY S., LOEWENSTEIN ANAT
December, 07th | 10:30 - 10:34
Potential of Home OCT guided treatment of nAMD
LOEWENSTEIN ANAT
Add to calendar
Potential of Home OCT guided treatment of nAMD
LOEWENSTEIN ANAT
Add to calendar
December, 07th | 10:34 - 10:38
Analysis of Aflibercept 8mg Real-World Data in Switzerland
ZWEIFEL SANDRINE
Add to calendar
Analysis of Aflibercept 8mg Real-World Data in Switzerland
ZWEIFEL SANDRINE
Add to calendar
December, 07th | 10:38 - 10:42
A Modular Multi-Task and Multi-Modal Deep Learning Framework to Determine Time for Starting Anti-VEGF Intervention for Neovascular Age-Related Macular Degeneration
HADZIAHMETOVIC MAJDA
Add to calendar
A Modular Multi-Task and Multi-Modal Deep Learning Framework to Determine Time for Starting Anti-VEGF Intervention for Neovascular Age-Related Macular Degeneration
HADZIAHMETOVIC MAJDA
Add to calendar
December, 07th | 10:42 - 10:46
Pooled safety analysis of the CANDELA, PHOTON, and PULSAR trials up to 96 weeks demonstrates comparable safety profiles with aflibercept 8 mg and 2 mg
MUNK MARION
Add to calendar
Pooled safety analysis of the CANDELA, PHOTON, and PULSAR trials up to 96 weeks demonstrates comparable safety profiles with aflibercept 8 mg and 2 mg
MUNK MARION
Add to calendar
December, 07th | 10:46 - 10:50
Intraocular pressure outcomes with intravitreal aflibercept 8 mg and 2 mg in patients with neovascular age-related macular degeneration through Week 96 of the PULSAR trial
GALE RICHARD
Add to calendar
Intraocular pressure outcomes with intravitreal aflibercept 8 mg and 2 mg in patients with neovascular age-related macular degeneration through Week 96 of the PULSAR trial
GALE RICHARD
Add to calendar
December, 07th | 10:50 - 10:54
FARWIDE UK 12 month experience – Largest Treatment Naïve Real World Dataset of Faricimab for NvAMD /DMO
PEARCE IAN
Add to calendar
FARWIDE UK 12 month experience – Largest Treatment Naïve Real World Dataset of Faricimab for NvAMD /DMO
PEARCE IAN
Add to calendar
December, 07th | 10:54 - 10:58
Aflibercept 8 mg in AMD. Sustained disease control in the PULSAR study
LANZETTA PAOLO
Add to calendar
Aflibercept 8 mg in AMD. Sustained disease control in the PULSAR study
LANZETTA PAOLO
Add to calendar
December, 07th | 10:58 - 11:02
Faricimab vs. Aflibercept for Neovascular AMD- Is it a Step Forward?
BRESSLER SUSAN
Add to calendar
Faricimab vs. Aflibercept for Neovascular AMD- Is it a Step Forward?
BRESSLER SUSAN
Add to calendar
December, 07th | 11:06 - 11:10
Drug clearance variability explains why many patients need more frequent intravitreal injections despite “longer-acting” agents
BROWN DAVID
Add to calendar
Drug clearance variability explains why many patients need more frequent intravitreal injections despite “longer-acting” agents
BROWN DAVID
Add to calendar
December, 07th | 11:10 - 11:14
Extended drug delivery to the posterior segment
DE-BOER CHARLES
Add to calendar
Extended drug delivery to the posterior segment
DE-BOER CHARLES
Add to calendar
